Company: STAA
Filing Date: 2025-10-20
Form Type: DEFA14A
Source: 0001193125-25-243044
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-10-20
Form: DEFA14A
Chunk 2
---
2025 |     | STAAR Surgical Company 
 By:                    |     | /s/ Stephen C. Farrell  |
|:-----------------------|:----|:-----------------------|:----|:------------------------|
|                        |     | Name:                  |     | Stephen C. Farrell      |
|                        |     | Title:                 |     | Chief Executive Officer |

Exhibit 99.1 STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025 LAKE FOREST, CA, October 20, 2025— STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer ®Lenses (EVO ICL ™) for vision correction, today announced preliminary net sales results for the third quarter ended September 26, 2025. STAAR is announcing its preliminary net sales results in advance of its quarterly earnings announcement to provide all stockholders with additional information regarding third quarter net sales performance and trends in advance of the STAAR Special Meeting of Stockholders scheduled for October 23, 2025, to vote on the Alcon merger proposal. Preliminary Net Sales Overview

| • |     | Preliminary net sales of $94.7 million, up 6.9% compared to $88.6 million in the prior year 
 period.                                                                                     |

| • |     | Preliminary net sales included $25.9 million related to the previously disclosed December 2024 ICL shipment                                                          
 that was subject to extended payment terms, and which was paid in full during the third quarter 2025 pursuant to such payment terms (the “December China Shipment”). |

| • |     | The year over year increase in preliminary net sales was primarily driven by the December China Shipment combined                                                                                          
 with 7.7% growth in net sales outside China, partially offset by lower new orders from distributors in China during the third quarter 2025, due in part to leaner inventory management during the quarter. |

As previously disclosed, the Company shipped $27.5 million of ICLs in December 2024 to one of its distributors in China for which the distributor requested extended payment terms through September 2025. Given the extended payment terms, net sales for the shipment were not recognized by the Company until payments were received. The Company recognized $1.6 million related to this shipment in the second quarter 2025 and the remaining $25.9 million in the